Enanta Pharmaceuticals Inc (ENTA)

29.17
0.15 0.52
NASDAQ : Health Care
Prev Close 29.02
Open 28.97
Day Low/High 28.60 / 29.28
52 Wk Low/High 16.75 / 51.89
Volume 235.57K
Avg Volume 243.80K
Exchange NASDAQ
Shares Outstanding 19.04M
Market Cap 552.58M
EPS 1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals To Present At Two Upcoming Investor Conferences

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Announces U.S. FDA Grants Priority Review To AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Announces U.S. FDA Grants Priority Review To AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes

Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes (GT1-6) Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie's...

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis

Enanta Pharmaceuticals To Host Conference Call On February 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals To Host Conference Call On February 8 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal First Quarter Ended December 31, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced results from AbbVie's...

Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) For Chronic Hepatitis C Achieved High SVR[12] Rates In Genotype 1 Japanese Patients

Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen Of Glecaprevir/Pibrentasvir (G/P) For Chronic Hepatitis C Achieved High SVR[12] Rates In Genotype 1 Japanese Patients

- 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P

Commit To Purchase Enanta Pharmaceuticals At $32, Earn 17.5% Annualized Using Options

Commit To Purchase Enanta Pharmaceuticals At $32, Earn 17.5% Annualized Using Options

Investors considering a purchase of Enanta Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $36.34/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Enanta Pharmaceuticals Announces Highlights Of Business Overview And Update On Its Research And Development Programs To Be Presented At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals Announces Highlights Of Business Overview And Update On Its Research And Development Programs To Be Presented At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the highlights of its...

FDA Grants Fast Track Designation To Enanta's FXR Agonist Candidate, EDP-305, For The Treatment Of NASH With Liver Fibrosis

FDA Grants Fast Track Designation To Enanta's FXR Agonist Candidate, EDP-305, For The Treatment Of NASH With Liver Fibrosis

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

Enanta Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Announces AbbVie's Submission Of NDA For Investigational, Pan-Genotypic HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Genotypes 1 Through 6 Of Chronic Hepatitis C Virus (HCV)

Enanta Pharmaceuticals Announces AbbVie's Submission Of NDA For Investigational, Pan-Genotypic HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Genotypes 1 Through 6 Of Chronic Hepatitis C Virus (HCV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie has...

AbbVie Submits New Drug Application To U.S. FDA For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

AbbVie Submits New Drug Application To U.S. FDA For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C

- If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes

Enanta Pharmaceuticals Announces The Appointment Of Dr. Lesley Russell To Its Board Of Directors

Enanta Pharmaceuticals Announces The Appointment Of Dr. Lesley Russell To Its Board Of Directors

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of...

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016

Enanta Pharmaceuticals Reports Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for...

Enanta Pharmaceuticals Announces AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

Enanta Pharmaceuticals Announces AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced 98 percent...

Enanta Announces Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C

Enanta Announces Eight Weeks Of Treatment With AbbVie's Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that AbbVie has...

Enanta Announces New Data On FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) At The Liver Meeting® 2016

Enanta Announces New Data On FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) At The Liver Meeting® 2016

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data...

Enanta Pharmaceuticals To Host Conference Call On November 21 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016

Enanta Pharmaceuticals To Host Conference Call On November 21 At 4:30 P.m. ET To Discuss Financial Results For Its Fiscal Fourth Quarter And Year Ended September 30, 2016

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to...

Enanta Pharmaceuticals To Present At The Credit Suisse 25th Annual Healthcare Conference

Enanta Pharmaceuticals To Present At The Credit Suisse 25th Annual Healthcare Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.

Enanta Pharmaceuticals Stock Sees Short Interest Move 15.2% Lower

Enanta Pharmaceuticals Stock Sees Short Interest Move 15.2% Lower

The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 369,069 share decrease in total short interest for Enanta Pharmaceuticals, Inc. , to 2,066,341, a decrease of 15.15% since 09/15/2016.

Enanta Pharmaceuticals Announces New Data Presentations At The Liver Meeting® 2016

Enanta Pharmaceuticals Announces New Data Presentations At The Liver Meeting® 2016

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that six poster...

Enanta Pharmaceuticals Announces AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

Enanta Pharmaceuticals Announces AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.

AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation

- Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)

Enanta Pharmaceuticals Presents Data On A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV) At The 10th Annual Respiratory Syncytial Virus Conference

Enanta Pharmaceuticals Presents Data On A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV) At The 10th Annual Respiratory Syncytial Virus Conference

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that a poster...

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-alcoholic Steatohepatitis (NASH)

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-alcoholic Steatohepatitis (NASH)

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has...

Commit To Buy Enanta Pharmaceuticals At $20, Earn 11.5% Annualized Using Options

Commit To Buy Enanta Pharmaceuticals At $20, Earn 11.5% Annualized Using Options

Investors eyeing a purchase of Enanta Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $26.27/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Rating: C (Hold)